



Assessing and Influencing Prognosis in Hepatocellular Carcinoma

Guest Editor:

Prof. Dr. Xavier Verhelst

Ghent University Hospital,
Department of Gastroenterology
and Hepatology, Corneel
Heymanslaan 10 – route 1241,
B9000 Ghent, Belgium

Deadline for manuscript
submissions:

closed (31 May 2022)

Message from the Guest Editor

Hepatocellular carcinoma (HCC) is a challenging disease to deal with. Patients are often diagnosed in advanced stages and, in these patients, therapeutic options are often limited to disease control rather than curative treatment. However, this group of patients is heterogeneous; hence, there is a need for better prognostication. First of all, this could allow medical professionals to provide better information to patients and this could support a better selection of the appropriate treatment for every single patient.

This evolution towards precision medicine is developing rapidly in all fields of medicine, as it is in HCC. This Special Issue will be entitled “Assessing and Influencing Prognosis in Hepatocellular Carcinoma” and will cover clinical and translational aspects. Indeed, this issue should provide a comprehensive overview of established or potential prognostic biomarkers in HCC. Review manuscripts of original scientific content will be included. This will be combined with manuscripts dealing with more fundamental aspects that can shed light on the heterogeneity of disease progression and could provide mechanistic clues as regards disease progression.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)